Abbott Laboratories vs. Viridian Therapeutics, Inc. Common Stock
ABT
Abbott Laboratories
$102.61 +0.37%
VS VRDNViridian Therapeutics, Inc. Common Stock
$21.58 -1.91%
Abbott Laboratories and Viridian Therapeutics, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| ABT | VRDN | |
|---|---|---|
| Market Cap | $177.55 billion | $2.49 billion |
| Revenue (TTM) | $46.59 billion | — |
| Net Income (TTM) | $5.42 billion | — |
ABT leads on 1 of 1 size & scale factors.
Valuation
| ABT | VRDN | |
|---|---|---|
| P/E Ratio | 33.21 | — |
| Price / Book | 3.43 | — |
| Price / Sales | 3.81 | — |
ABT and VRDN split the valuation factors evenly.
Profitability
| ABT | VRDN | |
|---|---|---|
| Net Margin | 11.65% | — |
| Return on Equity | 10.48% | — |
ABT and VRDN split the profitability factors evenly.
Dividend
| ABT | VRDN | |
|---|---|---|
| Dividend Yield | 2.46% | — |
| Payout Ratio | 81.55 | — |
ABT and VRDN split the dividend factors evenly.
Risk & Sentiment
| ABT | VRDN | |
|---|---|---|
| Short Interest | 0.57% | 0.13% |
VRDN leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, VRDN overview, VRDN financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.